Aquestive Therapeutics, Inc. (AQST) Stock Analysis

Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

Thu, September 17, 2026 at 11:00 AM UTC 2 min read

Aquestive Therapeutics has announced the resubmission of its New Drug Application (NDA) to the FDA for Anaphylm™ (dibutepinephrine) sublingual film, a treatment aimed at addressing severe allergic reactions. This resubmission is significant for investors as it could pave the way for potential FDA approval, enhancing the company's product portfolio and revenue prospects. Successful approval may also bolster investor confidence and positively impact AQST's stock performance in the near future.

Read full article →

Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus

Tue, September 8, 2026 at 2:07 AM UTC 3 min read

Aquestive Therapeutics (AQST) has announced a renewed focus on its Anaphylm product, which is designed to treat severe allergic reactions. This development is significant for investors as it could potentially lead to new revenue streams and market opportunities, especially given the increasing demand for effective allergy treatments. The company's strategic pivot highlights its commitment to advancing its product pipeline, which may enhance investor confidence moving forward.

Read full article →